Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

MMJ Group Holdings - Management Agreement with Embark Ventures Inc Update (ASX:MMJ)

MMJ Group Holdings Limited (ASX:MMJ) ("MMJ"), is an Australian listed company whose core business is holding minority investments along the cannabis value-chain in Australia, Canada and Eu...read more

Cyclopharm - USFDA Approval Progress for Technegas and Business Update (ASX:CYC)

Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its progress towards gaining United States Food and Drug Administration (“USFDA”) approval to begin sales of T...read more

MMJ Group Holdings Investment Portfolio Report December 2020 (ASX:MMJ)

MMJ Group Holdings Limited (ASX: MMJ/OTC Code MMJJF) ("MMJ") is an Australian-listed company whose core business is holding minority investments along the cannabis value-chain in Australia...read more

Noxopharm Announces NOXCOVID Study Advances (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), announces that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the ...read more

Immutep - Recruitment of head & neck cancer patients completed for ph2 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed t...read more

Noxopharm Shareholder Update 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides this shareholder update as a summary of R&D progress in 2020 and a guide to what 2021 is expected to hol...read more

Immutep - Resignation and Appointment of Joint Company Secretary (ASX:IMM)

ASX and NASDAQ listed biotechnology company Immutep Limited (“Immutep“ or the “Company“), advises that Mr Tom Bloomfield has resigned as the joint Company Secretary of the Co...read more

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Appendix 2A (ASX:IMM)

To view the Application for quotation of +securities, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the notice of change of interests of substantial holder, download the attached PDF.

Immutep granted US patent for eftilagimod alpha with a PD-1 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is ...read more